Drug Profile
CC 10015
Alternative Names: CC-10015Latest Information Update: 03 Dec 2019
Price :
$50
*
At a glance
- Originator Celgene Corporation
- Class Phthalimides; Piperidones; Small molecules
- Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Systemic scleroderma
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 16 Jul 2016 No recent reports of development identified for phase-I development in Systemic-scleroderma in USA (PO)